Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $120,984.98 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 7,459 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $120,984.98. Following the sale, the chief executive officer directly owned 228,527 shares of the company’s stock, valued at approximately $3,706,707.94. This trade represents a 3.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Stock Performance

Shares of NASDAQ PSNL traded up $0.12 during mid-day trading on Tuesday, hitting $16.36. The stock had a trading volume of 1,369,078 shares, compared to its average volume of 2,690,633. Personalis, Inc. has a 1 year low of $4.95 and a 1 year high of $18.89. The business has a 50 day moving average price of $15.06 and a two-hundred day moving average price of $10.89. The firm has a market cap of $1.71 billion, a P/E ratio of -15.01 and a beta of 2.31.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Equities research analysts predict that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Institutional Trading of Personalis

Hedge funds have recently modified their holdings of the business. Merck & Co. Inc. purchased a new position in Personalis during the second quarter valued at $188,202,236. BlackRock Inc. bought a new stake in Personalis in the second quarter worth $94,905,000. Bank of America Corp DE purchased a new stake in shares of Personalis in the second quarter worth $24,395,000. AIGH Capital Management LLC purchased a new stake in shares of Personalis in the second quarter worth $22,981,000. Finally, Next Century Growth Investors LLC bought a new position in shares of Personalis during the fourth quarter valued at $4,970,000. Institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PSNL. Craig Hallum lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. BTIG Research upped their price target on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Lake Street Capital cut Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a report on Monday, July 20th. Finally, Morgan Stanley lifted their price objective on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Personalis currently has an average rating of “Hold” and a consensus price target of $14.54.

Personalis Company Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.